Feng Zhou

TL;DR: A retrospective study on 13,981 patients with COVID-19 in Hubei Province, China found that the risk for 28-day all-cause mortality was 5.2% and 9.4% in the matched statin and non-statin groups, respectively, with a hazard ratio 0.58, implying the potential benefits of statin therapy in hospitalized subjects with CO VID-19.

TL;DR: To reveal the hepatic injury related to this disease and its clinical significance, a multicenter retrospective cohort study that included 5,771 adult patients with COVID‐19 pneumonia in Hubei Province was conducted.

TL;DR: Wang et al. as discussed by the authors evaluated the epidemiology, risk factors, complications, and management of nonalcoholic fatty liver disease in China through a systematic review and meta-analysis, and found that NAFLD is positively correlated with the incidence of extrahepatic tumors, diabetes, cardiovascular disease and metabolic syndrome.

TL;DR: Wang et al. as mentioned in this paper summarized eight epidemiological features of NAFLD in China over the past two decades using systematic review and meta-analysis methodology. And they revealed that there is a strong ethnic difference in body mass index (BMI) and genetic risk of nonalcoholic fatty liver disease compared with the US population.

TL;DR: Cardiac biomarker elevations are significantly associated with 28-day death in patients with COVID-19 and the newly established cutoff levels of CO VID-19–associated cardiac biomarkers may serve as useful criteria for the future prospective studies and clinical trials.